Dr. John G. Geisler

Dr. John G. Geisler |Clyto Access

Founder & Chief Scientific Officer at Mitochon Pharmaceuticals, USA

Keynote Speaker

Expertise: Diabetes, Metabolic drug discovery


John G. Geisler, Ph.D.,Founder & Chief Scientific Officer,Mitochon Pharmaceuticals, Inc.– Expertise in drug discovery in metabolic disease (Pfizer, Ionis, JnJ) with a primary role bringing forward the inception of new ideas. By striving to working at the root of problems and years of attempting to partition lipids to restore insulin sensitivity, Dr. Geisler has built an expertise in mitochondrial energy expenditure. From this work, stemmed a broader understanding of new mitochondrial targeted applications, and significant gaps of pharmacological interventions for insidious movement disorders and neurodegenerative diseases. Dr. Geisler holds a Ph.D. in Mammalian Genetics from University of Tennessee, conducted at Oak Ridge National Laboratories (ORNL), and a fellowship at Yale University, focused on the physiology and whole-body flux. Mitochon Pharmaceuticals was launched Nov 2014 along with co-founder, Robert Alonso and is now clinically staged.



Title: The Uses of Mitochondrial Specific Protonophore,MP101, as a Broad Spectrum Agent for Neuromuscular and Neurodegenerative Disorders


Although mitochondrial dysfunction has been associated with a number of neurodegenerative disorders, currently, there are no “disease modifying”mitochondrial drug treatments. MP101, an oral brain penetrant, mitochondria-specific protonophore that increases energy expenditure, cAMP, CREB, induces neurotrophin/myokine BDNF, lowers cellular stress (ROSs)/mTOR, and improves calcium handling at weight neutral/preserving doses,may have the merit as a once-per-day treatment for a host of insidious diseases. In representative models of Parkinson’s,Alzheimer’s, Huntington’s, epilepsy, TBI, hearing loss, Duchenne Muscular Dystrophy, Optic Neuritis, and Multiple Sclerosis, under chronic oral administration, we have demonstrated that MP101 provideda disease modifying effect. Although these diseases are genetically unrelated and some with no known genetic cause, it appears that improving mitochondrial resilience with MP101 may provide ubiquitous protective pharmacology for a spectrum of insidious diseases, beyond what is shown here, including metabolic disorders. BDNF has anti-diabetic qualities and the pharmacology of MP101 should improve insulin sensitivity even at these weight neutral doses. Since MP101 is a weak acid and “acids go to base”, the drug specifically targets the mitochondria, the only organelle within the cell with a pH basic environment. The MOA of this broad neuroprotection stems from the unique pleiotrophic effects of modulating the mitochondrial membrane potential andthereby the entire organelle’s physiology with a protonophore. The actions are initially non-genomic vs. a protein pathway, however this action results in a cascade of mitochondrial/cellular remodeling in favor of neuroprotection. The fact that this organelle is highly evolutionarily conserved,there are considerable advantages that predict strongtranslation, precisely our next step now with the completion of the GLP IND enabling studies. Phase I begins in 1Q18 in NHV, with Huntington Disease, DMD and Optic Neuritis as our following Phase II indications.Success here, will open a new door and a new platform to treat truly unmet medical needs.


Related Conferences :

International Diabetes and Degenerative Diseases Conference